KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Acquisitions & DivestmentsChange in CashDivestmentsDividends Paid - CommonFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activities
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Royalty Pharma (RPRX) Change in Acquisitions & Divestments (2019 - 2025)

Royalty Pharma's Change in Acquisitions & Divestments history spans 6 years, with the latest figure at $2.9 million for Q4 2025.

  • For Q4 2025, Change in Acquisitions & Divestments rose 140.0% year-over-year to $2.9 million; the TTM value through Dec 2025 reached $11.1 million, changed N/A, while the annual FY2025 figure was $21.2 million, N/A changed from the prior year.
  • Change in Acquisitions & Divestments for Q4 2025 was $2.9 million at Royalty Pharma, down from $12.6 million in the prior quarter.
  • Across five years, Change in Acquisitions & Divestments topped out at $1.6 billion in Q4 2021 and bottomed at -$821.8 million in Q3 2021.
  • The 5-year median for Change in Acquisitions & Divestments is $15.6 million (2022), against an average of $162.0 million.
  • The largest YoY upside for Change in Acquisitions & Divestments was 51599.2% in 2021 against a maximum downside of 144.58% in 2021.
  • A 5-year view of Change in Acquisitions & Divestments shows it stood at $1.6 billion in 2021, then plummeted by 92.54% to $115.6 million in 2022, then plummeted by 78.91% to $24.4 million in 2023, then tumbled by 129.52% to -$7.2 million in 2024, then soared by 140.0% to $2.9 million in 2025.
  • Per Business Quant, the three most recent readings for RPRX's Change in Acquisitions & Divestments are $2.9 million (Q4 2025), $12.6 million (Q1 2025), and -$7.2 million (Q4 2024).